Novel Therapeutic Perspectives in the Management of DLBCL: The Role of Antibody-Drug Conjugates and Bispecific Antibodies

Novel Therapeutic Perspectives in the Management of DLBCL: The Role of Antibody-Drug Conjugates and Bispecific Antibodies is organized by Med Learning Group.

Description:
This Community Whiteboard ECHO Series and Online Enduring activity is designed to increase the multi-disciplinary oncology care team recognition of the role of targeted and bispecific antibodies in management of relapsed/refractory DLBCL; strengthen their understanding of clinical trial outcomes and adverse events with targeted and bispecific antibodies; and improve their awareness of multidisciplinary best practices for managing adverse events from targeted therapies.

Learning Objectives:
Upon completing this program, attendees should be able to:

• Evaluate novel targets in the management of diffuse large B-cell lymphoma (DLBCL).
• Analyze the outcomes of key trials in DLBCL management, including ongoing trials of novel therapies for the management of relapsed/refractory disease.
• Recognize potential adverse events associated with novel therapies for DLBCL management and best practices for multidisciplinary management.